PKCs in thrombus formation.
Montréal, Canada. In Pathol Biol (paris), Dec 2015
In addition, PKCβ by interacting with its receptor RACK1 has been implicated in the primary phases of signaling via the αIIbβ3 and finally PKCɛ appears to be involved in platelet function downstream GPVI.
The platelet Fc receptor, FcγRIIa.
Melbourne, Australia. In Immunol Rev, Nov 2015
Finally, we present some new data investigating whether levels of the extracellular ligand-binding region of platelet glycoprotein VI which is rapidly shed upon engagement of platelet FcγRIIa by autoantibodies, can report on the presence of pathological anti-heparin/platelet factor 4 immune complexes and thus identify patients with pathological autoantibodies who are at the greatest risk of developing life-threatening thrombosis in the setting of heparin-induced thrombocytopenia.
Antiplatelet drugs: which targets for which treatments?
Strasbourg, France. In J Thromb Haemost, Jun 2015
New targets including the collagen receptor, glycoprotein VI (GPVI), and the GPIb-von Willebrand factor axis, governing platelet interaction with the diseased vessel wall, should enable us to complete the armamentarium of antiplatelet drugs.
Focusing on plasma glycoprotein VI.
Melbourne, Australia. In Thromb Haemost, 2012
analysis of platelet GPVI, a unique platelet-specific receptor with uses in diagnosis and/or disease prevention [review]
Gene variants associated with deep vein thrombosis.
Leiden, Netherlands. In Jama, 2008
false discovery rate < or =.10): rs13146272 in CYP4V2 (risk allele frequency, 0.64), rs2227589 in SERPINC1 (risk allele frequency, 0.10), and rs1613662 in GP6 (risk allele frequency, 0.84).